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Acute cholestasis-induced renal failure: Effects of antioxidants and creatinine clearance is frequently decreased to 60% of
ligands for the thromboxane A2 receptor. normal in patients with biliary obstruction [3].
Background. Acute biliary obstruction is associated with the devel-
Recently, a role for free radicals has been postulatedopment of renal impairment and oxidative stress. The F2-isoprostanes,
formed during oxidant injury, are renal vasoconstrictors acting via in the renal dysfunction of biliary obstruction [4]. One
thromboxane (TX)-like receptors. We determined whether the forma- of the major targets of free radical injury is unsaturated
tion of F2-isoprostanes is increased in experimental cholestasis and fatty acids, which undergo peroxidation to lipid hydro-whether thiol containing antioxidants or ligands for the TXA2 receptor
could improve renal function. peroxides and a variety of decomposition products, such
Methods. The effects on renal function of acute bile duct ligation as aldehydes or isoprostanes. Sokol et al have observed
(BDL) in the rat were studied for two days. The consequences of adminis-
a rapid increase in intracellular hydroperoxide and thio-tration of N-acetylcysteine (NAC), a-lipoic acid (LA), the TX receptor
antagonist (TXRA) BAYu3405, or placebo were then examined. barbituric acid reactive substances within hours of expo-
Results. BDL caused a reduction in creatinine clearance from 1.10 6 sure of hepatocytes to bile acids in vitro [5]. Panozzo et
0.05 to 0.55 6 0.05 ml/min and sodium excretion from 52 6 3 to 17 6
al have reported a sixfold increase in serum thiobarbituric3 mmol/hr. Urinary F2-isoprostanes increased from 14 6 2 to 197 6 22
acid reactive substances at day 2 following acute bile ductpg/ml following BDL. Renal functional changes were ameliorated by
NAC (creatinine clearance 0.73 6 0.05 ml/min), LA (0.64 6 0.03 ml/ ligation (BDL) [6, 7]. In addition, patients with biliary
min), and a TXRA (0.90 6 0.15 ml/min); P , 0.05. Similarly, sodium obstruction have been shown to have elevated circulatingexcretion was increased from 17 6 3 mmol/hr (placebo) to 34 6 3 mmol/
lipid peroxides and impaired antioxidant defenses [8].hr (NAC), 29 6 3 mmol/hr (LA), and 38 6 5 mmol/hr (TXRA); P ,
0.005. Hepatic glutathione concentrations increased from 6.5 6 0.3 Recently, measurement of F2-isoprostanes in plasma or
mmol/g (normal liver) to 8.8 6 0.5 mmol/g (NAC) and 7.7 6 0.3 mmol/g urine has emerged as one of the most reliable approaches(LA), P , 0.01. However, only LA markedly inhibited F2-isoprostane
to assess lipid peroxidation in vivo. It has been used toformation (197 6 22 to 36 6 11 pg/ml creatinine clearance; P , 0.05).
Urinary TXB2 excretion was elevated after BDL (2.2 6 0.5 to 111.1 6 measure lipid peroxidation in a number of models of
20.3 pg/min) but was unaffected by NAC and LA. free radical injury and to explore the role of free radicalsConclusion. NAC, LA, and TXRA can partially prevent renal dys-
in several disease processes in humans such as the hepa-function in experimental cholestasis. The effects of the antioxidants
are independent of their ability to inhibit lipid peroxidation or TX torenal syndrome [9], scleroderma [10], and atheroscle-
synthesis. rosis [11]. Moreover, the F2-isoprostanes are biologically
active, causing release of endothelin-1 [12] and renal vaso-
constriction via a thromboxane (TX) A2-like receptor [13].
Abnormalities of renal function are well described Kramer, Schwarting and Backer have previously dem-
in cholestasis, but their etiology remains uncertain. In onstrated that administration of a TX receptor antagonist
humans, there is a paucity of data concerning renal func- (TXRA) prevented the decline in renal function in the
tion during acute biliary obstruction prior to surgery. bile duct–ligated rat. These authors attributed this to
However, 10% to 15% of patients undergoing surgical antagonism of TXA2, the levels of which increased by
drainage suffer significant morbidity and mortality due twofold [14]. However, because the renal actions of F2-
to renal failure [1, 2]. Previous studies have shown that isoprostanes are also blocked by TX receptor antago-
nism [13], the blocking of an F2-isoprostane effector path-
way is an alternative interpretation of this data.Received for publication March 18, 1998
In this study, we have therefore evaluated the effectsand in revised form July 23, 1998
Accepted for publication August 15, 1998 of three treatments, namely the antioxidants N-acetyl-
cysteine (NAC) and a-lipoic acid (LA) and a TXRA, 1999 by the International Society of Nephrology
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on both the formation of F2-isoprostanes and renal func- were diluted, and deuterated internal standard was
tion in acute BDL rat. added. Solid phase extraction was then performed fol-
lowed by thin layer chromatography on silica LK6D
(Whatman, Inc., Clifton, NJ, USA) in chloroform:metha-METHODS
nol:acetic acid:water (86:14:1:0.8 ml). The free F2-iso-
Animals prostanes were then scraped from the plates, dried down,
All animal experiments were performed according to and derivatized to the pentafluorobenzyl ester. They
the United Kingdom Home Office guidelines under the were then subjected to a second thin layer chromatogra-
Animals in Scientific Procedures Act 1986. Male Sprague- phy stage, converted to a trimethylsilyl ether derivative,
Dawley rats weighing approximately 250 g were obtained and analyzed by negative ion chemical ionization–gas
from the Comparative Biology Unit, Royal Free Hospi- chromatography mass spectrometry. Ions were then
tal School of Medicine. All animals were housed in the monitored at 569 and 573. Urinary excretion of F2-iso-
Comparative Biology Unit on a standard diet with a light prostanes was corrected for creatinine clearance (that is,
cycle of 12 hours on and 12 hours off, at a temperature excretion rate/creatinine clearance) to take into account
of 19 to 238C, and a humidity of approximately 50%. the widely differing degrees of renal dysfunction between
Baseline 24-hour urine collections were performed with animals and controls. Because clearance and excretion
free access to food and water immediately prior to opera- rate are both a function of time, this is calculated as:
tion. Rats were anesthetized with i.m. Hypnorm (Janssen
Pharmaceuticals, Oxford, UK) and i.p. diazepam (Du-
mex Ltd, Tring, UK) and underwent both triple BDL and
3Urinary F2-isoprostanes(pg/ml) 4 3 3
plasma creatinine
(mmol/liter) 4
Urine creatinine (mmol/liter)surgical division (BDL) or sham manipulation (sham)
of the bile ducts. The animals were allowed to recover Results are expressed as urinary F2-isoprostanes pg/mlovernight and were then returned to the metabolic cage creatinine clearance.
for two further 24-hour metabolic studies, designated Internal standards ([D4]-8-isoprostaglandin-F2a [8-iso-day 2 and day 3, respectively. All animals were given PGF2a] and [D4]-PGF2a) were from Cayman Chemicalstreatment with intraperitoneal injection for 24 hours (Ann Arbor, MI, USA). All organic reagents were pur-
prior to, during, and after surgery. Following recovery, chased from Sigma-Aldrich (Poole, Dorset, UK).
the animals were allowed free access to water and stan-
dard laboratory diet. Animals were exsanguinated under Measurement of urinary TXB2
anesthesia at the end of the study period. Blood was
Urinary TXA2 excretion was estimated on urine fromcollected from the inferior vena cava into ethylenedi-
the preoperative and day 2 urine collections. This wasaminetetraacetic acid tubes, centrifuged immediately at
performed using an enzyme immunoassay kit measuring48C. Plasma and urine were frozen and stored at 2808C
TXB2, the stable urinary metabolite of TXA2 (Caymanuntil analysis.
Chemical). The antibody specificity was as follows: TXB2
100%, 2,3,dinor TXB2 8.2%, PGD2 0.44%, PGF2a 0.22%,Treatments
11–dehydro TXB2 0.2%, PGF1a 0.05%, PGE2/6-ketoPGF1a/Sham-operated control animals were given 2 ml 0.9%
2,3-dinor-6-ketoPGF1a/13,14-dihydro-5-keto PGF2a/LTB4,sodium chloride (N 5 8) twice daily by intraperitoneal
all ,0.01%. Results were expressed as pg/min.injection, whereas placebo-treated BDL animals were
given 2 ml of 150 mmol Tris buffer pH 7.4, the vehicle Renal and hepatic function
for LA and TXRA (N 5 12). NAC (Evans Medical Ltd,
Plasma and urine creatinine were measured using anSurrey, UK) was given at a dose of 200 mg/kg in 2 ml
autoanalyzer (Hitachi, Tokyo, Japan) by a kinetic colori-of 0.9% sodium chloride i.p. twice a day (N 5 16). LA
metric method. Converting bilirubin to biliverdin with(Sigma, Poole, Dorset, UK) was given as a dose of 10
potassium hexacyanoferrate (III) and using a dual wave-mg/kg in 4 ml of TRIS buffer corrected to pH 7.4 i.p.
length absorption method minimized bilirubin interfer-once daily (N 5 18). The TXRA (BAYu3405; Bayer,
ence with this assay. Plasma aspartate transaminase (AST),Wuppertal, Germany) was given at a total dose of 10
albumin, and bilirubin as well as plasma and urine so-mg/kg/day given as 2 ml intraperitoneal injections in Tris
dium were determined by the same autoanalyzer.buffer corrected to pH 7.4 twice daily (N 5 12).
Hepatic glutathioneMeasurement of urinary F2-isoprostanes
Hepatic levels of glutathione were estimated using aUrinary F2-isoprostanes in urine were extracted and
colorimetric assay kit (Oxis International, Portland, OR,quantitated using a stable isotope dilution gas chromato-
USA) measuring total glutathione. Hepatic glutathionegraph–mass spectrometry method as previously described
[15] with the modifications outlined. In brief, samples was measured following homogenization and precipita-
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Table 1. Plasma hepatic biochemistry at sacrifice after BDL (F2-isoprostanes 180 6 19 pg/ml creatinine clearance, P 5and treatment
NS). Treatment with TXRA had no effect on F2-isopros-
Bilirubin AST Albumin tane excretion following BDL, with urinary values of
Treatment lmol/liter IU/liter g/liter 204 6 28 and 177 6 21 pg/ml creatinine clearance at
Sham 2 6 0 111 6 13 31 6 1 day 2 and day 3, respectively (P 5 NS).
Placebo 185 6 9 1419 6 86 27 6 1
NAC 200 6 10 1196 6 91a 27 6 1
Renal function and sodium excretionLA 161 6 6 1824 6 205 27 6 1
TXRA 169 6 7 983 6 78b 29 6 0.4 All groups had similar baseline renal function (1.10 6
NAC and TXRA showed significantly lower levels of AST indicating a possible 0.05 ml/min) but decreased by 50% between days 2 and
protective effect on hepatic function.
Abbreviations are: AST, aspartate transaminase; NAD, N-acetylcysteine; 3 after BDL (0.55 6 0.05 ml/min, P , 0.001) (Fig. 2).
TXRA, thromboxane receptor antagonist; LA, a-lipoic acid; BDL, bile duct Creatinine clearance was unaffected by sham operationligation.
aP , 0.02, b P , 0.002 compared with placebo treatment (1.15 6 0.06 pre-operative to 1.20 6 0.06 ml/min post-
operative measurement). The administration of NAC,
LA, or TXRA partially prevented the fall in creatinine
clearance. NAC improved creatinine clearance from
tion in metaphosphoric acid, followed by filtration 0.55 6 0.05 to 0.73 6 0.05 ml/min at day 2 and 0.75 6
through 30,000 molecular weight cut-off filters. Results 0.03 ml/min (P , 0.05) at day 3. LA had a small but
are expressed as mmol/g liver. statistically significant effect on renal function at two days
(0.64 6 0.03 ml/min, P , 0.05), but not at three daysStatistics
(0.65 6 0.04 ml/min, P 5 NS). Because the renal effects
All results are expressed as mean 6 sem, and statistical of F2-isoprostanes are mediated via a TX-like receptor,evaluation was carried out using an unpaired t-test. Results we evaluated the effects of a TXRA (BAY u3406) on
were considered significant when the P value was ,0.05. renal function. TXRA had the most marked effect on
renal function, with creatinine clearance increasing to
0.90 6 0.15 ml/min and 0.89 6 0.16 ml/min at days 2 and 3,RESULTS
respectively (P , 0.05).Liver function
Baseline sodium excretion was similar in all the groupsBiliary obstruction was confirmed by an increase in
at 52 6 3 mmol/hr (P 5 NS) and was unchanged by shamplasma bilirubin from 2 6 2 to 185 6 9 mmol/liter and
operation (48 6 3 mmol/hr). Following BDL, sodiumAST from 111 6 13 to 1419 6 86 IU/liter (Table 1). The
excretion fell to 17 6 3 mmol/hr on day 2 (P , 0.05),rise in AST was significantly attenuated by TXRA (983 6
but was increased by NAC, LA, and TXRA to 34 6 5,78 IU/liter, P , 0.002) and NAC (1196 6 91 IU/liter, P ,
29 6 3, and 38 6 5 mmol/hr, respectively, on day 2 (P ,0.02), but LA had no significant effect (1824 6 205 IU/
0.005), with similar results on day 3 (Fig. 3).liter, P 5 NS). Thus, administration of both NAC and
the TXRA decreased hepatic injury, which is consistent Urinary TXB2with previous data [16, 17].
Urinary TXB2 was estimated on baseline urine (N 5 7)Plasma albumin was not significantly different between
and urine from the day 2 collection in the placebo (N 5 7),BDL treated groups (27 6 1 g/liter), but this was lower
NAC (N 5 6), and LA (N 5 6) groups. Urinary TXB2than sham-operated animals (31 6 1 g/liter, P , 0.05).
excretion increased from a baseline of 2.2 6 1 to 111 6
Urinary F2-isoprostane excretion 25 pg/min on day 2 (P , 0.001). However, there was no
difference between placebo and NAC 115 6 39 pg/minBaseline urinary F2-isoprostane excretion was similar
and LA 109 6 28 pg/min groups (P 5 NS).in the sham, placebo control, and NAC treated groups,
with a mean level of 14 6 2 pg/ml creatinine clearance,
Hepatic glutathionerespectively. Following BDL, F2-isoprostane excretion
Hepatic levels of glutathione were measured in normalincreased by approximately 20-fold to 197 6 22 and 158 6
animals and after BDL following treatment with placebo,18 pg/ml creatinine clearance (P , 0.01) at days 2 and 3,
NAC, and LA (N 5 7 in each group). Tissue glutathionerespectively, indicative of lipid peroxidation (Fig. 1). Ad-
was significantly increased by treatment with NAC (8.8 6ministration of LA significantly inhibited F2-isoprostane
0.5 mmol/g) compared with placebo-treated control ani-production with levels of 36 6 11 pg/ml creatinine clear-
mals (6.8 6 0.4 mmol/g, P , 0.01). Although the glutathi-ance and 49 6 18 pg/ml creatinine clearance at day 2
one content of liver in the LA group (7.7 6 0.3 mmol/g)and day 3, respectively (P , 0.05). NAC partially attenu-
was increased compared with unoperated normal ani-ated lipid peroxidation within the first two days (urinary
mals (6.5 6 0.3 mmol/g, P , 0.01), it was not significantF2-isoprostane levels being 145 6 14 pg/ml creatinine
clearance, P , 0.05), but this effect was lost by 3 days compared with the control group (Fig. 4).
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Fig. 1. Urinary F2-isoprostane excretion in-
creased acutely immediately following bile duct
ligation in the rat, indicative of lipid peroxida-
tion. Lipid peroxidation occurs early within 2
days. Symbols are: ( ) placebo; ( ) a-lipolic
acid (LA); ( ) N-acetylcysteine (NAC); ( )
thromboxane receptor antagonist BAYu3405
(TXRA). Urinary isoprostanes were signifi-
cantly reduced by LA but not by NAC or TXRA
(#P , 0.01, *P , 0.001).
Fig. 2. Creatinine clearance after bile duct li-
gation in the rat. Creatinine clearance was
significantly higher in the groups treated with
LA (a-lipoic acid; ), NAC (N-acetylcys-
teine; ) and TXRA (thromboxane receptor
antagonist; ) at day 2 (placebo, ). How-
ever, only NAC and TXRA remained signifi-
cant 3 days after acute bile duct ligation. (*P ,
0.05). There was no reduction in creatinine
clearance after sham operation.
DISCUSSION min E, and selenium levels, and reductions in the activity
of hepatic glutathione peroxidase and glutathione-S-Reactive oxygen species have been implicated in the
transferase [7, 19–21]. However, these reductions werepathogenesis of a number of disease processes. Evidence
seen at later time points than those measured in ourto date suggests that free radical-mediated lipid per-
study. More recently, the measurement of the F2-isopros-oxidation occurs in the rat following BDL. The lipid
tanes, which are formed by the action of free radicalsperoxidation breakdown products, malonaldehyde and
on arachidonic acid, has emerged as one of the most4-hydroxynonenal, have been reported to be increased
reliable indices of assessing oxidant stress in vivo. More-by approximately threefold at five weeks [18] in the liver
over, the F2-isoprostanes have potent biological activity–of bile duct-ligated rats. In addition, host defense against
causing renal vasoconstriction and an acute decrease inoxidant stress is impaired in this model, with decreased
hepatic and erythrocyte levels of glutathione, plasma vita- glomerular filtration rate when infused in vivo, both fea-
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Fig. 3. Urine sodium is decreased following
acute bile duct ligation. This effect is abro-
gated by NAC ( ), LA ( ) and TXRA ( ;
placebo is ; *P , 0.05, #P . 0.005).
widely used water-soluble antioxidant with important
hepatic and renal protective properties. It is readily taken
into cells where it is converted to cysteine, the rate-
limiting substrate for glutathione formation [24]. Thus,
NAC increases intracellular glutathione levels conferring
antioxidant protection. We were able to demonstrate
that we had increased hepatic glutathione concentra-
tions, confirming that the drug had been effectively ad-
ministered. LA is a low molecular weight thiol with im-
portant antioxidant functions, which has been used in
the treatment of diabetic neuropathy [25]. It is readily
absorbed and taken up into cells and tissues, where it isFig. 4. Hepatic glutathione concentration was increased with respect
interconverted with its reduced form, dihydrolipoic acid.to normal rat livers in the NAC and LA groups. There was no effect
on hepatic glutathione at 3 days of bile duct ligation (BDL) with placebo These two forms of lipoic acid are capable of scavenging
treatment (*P , 0.05, #P , 0.01). hydroxyl, hypochlorous, and peroxynitrite radicals di-
rectly in the fluid phase, in addition to being able to
regenerate of vitamins C and E and cellular glutathione
[26]. There were contrasting effects of both NAC andtures of which are known to occur in the BDL model
LA on isoprostane production. Whereas LA virtually[22]. These renal actions are blocked by TXRAs. Based
completely suppressed the urinary levels of F2-isopros-on preliminary studies [23], we hypothesized that the
tanes, NAC only had a minimal impact at day 2, witheffects observed by Kramer, Schwarting and Backer of
no significant effect at day 3. As anticipated, TXRA hadDaltroban [14], a TXRA, on renal function were due
no effect on urinary F2-isoprostane excretion because itsto F2-isoprostanes formed during free radical–mediated
effects are to antagonize their action, rather than inhibitinjury and which became acutely elevated post-BDL.
their production.This hypothesis was strengthened by the observation
Both NAC and LA caused small but significantof Kramer et al that urinary TXB2 was only modestly
improvement in renal function in this model, althoughincreased, in this study by twofold compared with the
the response to LA was marginal (0.55 to 0.64 ml/min).20-fold elevation of F2-isoprostanes [14].
The most striking and consistent observation was that,Our initial approach was to determine whether two
although LA was very effective at preventing isopros-strategies aimed at repleting or replacing cellular reduc-
tane formation, it was the least effective at preservinging equivalents, such as glutathione (NAC) or by direct
renal function in this model. Thus, the hypothesis thatscavenging of radicals (LA), could suppress F2-isopros-
tane formation and improve renal function. NAC is a F2-isoprostanes are directly and causally related to the
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renal dysfunction observed now seems unlikely. Neverthe- and has a good safety profile. This is the first report, to
less, these data do not completely exclude a role for oxi- our knowledge, of beneficial effects of NAC on renal
dant stress in the pathogenesis of renal dysfunction in function in cholestasis, and whatever the mode of action,
BDL, as both NAC and LA caused significant improve- the observation that NAC has beneficial effects on renal
ment of renal function in this model. The observation that function is worth exploring further.
the TXRA BAYu3405 improved renal function in this We conclude that both NAC and LA improve renal
model confirms the findings of Kramer et al [14]. Kramer function in experimental cholestasis. The mechanism of
et al observed that urinary TXB2 increased from 57 to action is unknown but is unlikely to involve inhibition
117 pmol · 24 hr21 · 100 g21 following BDL [14]. For TXA2 or lipid peroxidation. Studies are needed to deter-
comparison, basal TXB2 excretion in our animals was 3 6 1 mine the effect of these or similar agents in patients with
pmol · 24 hr21 · 100 g21, increasing to 184 6 40 pmol · biliary obstruction.
24 hr—1 · 100 g21 following BDL. These levels were es-
sentially unchanged by NAC (166 6 54 pmol · 24 hr21 · ACKNOWLEDGMENTS
100 g21) or LA (173 6 45 pmol · 24 hr21 · 100 g21). Thus,
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APPENDIXalthough renal formation of TX may be an important
Abbreviations used in this article are: AST, aspartate transaminase;mediator of renal vasoconstriction in biliary obstruction,
BDL, bile duct ligation; 8-iso-PGF2a, 8-isoprostaglandin-F2a; LA,this is not the mechanism through which LA and NAC a-lipoic acid; NAC, N-acetylcysteine; TX, thromboxane; TXRA,
are effective. thromboxane receptor antagonist.
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